Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00009 JCO Precision Oncology no. 6 (2022) e2200009. Published online June 23, 2022. PMID: 35737914 Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung Fangdi Sun, MD1xFangdi SunSearch for articles by this author; James P. Grenert, MD, PhD2xJames P. GrenertSearch for articles by this author; Lisa Tan, BS1xLisa TanSearch for articles by this author; Jessica Van Ziffle , PhD2xJessica Van ZiffleSearch for articles by this author; Nancy M. Joseph, MD, PhD2xNancy M. JosephSearch for articles by this author; Claire K. Mulvey , MD1xClaire K. MulveySearch for articles by this author; and Emily Bergsland , MD1xEmily BergslandSearch for articles by this author Show More 1Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA2Department of Pathology, University of California, San Francisco, San Francisco, CA https://doi.org/10.1200/PO.22.00009 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported by the National Cancer Institute of the National Institutes of Health under award No. P30CA082103.AUTHOR CONTRIBUTIONSConception and design: Fangdi Sun, Emily BergslandCollection and assembly of data: Fangdi Sun, Lisa Tan, Jessica Van ZiffleData analysis and interpretation: Fangdi Sun, James P. Grenert, Nancy M. Joseph, Claire K. Mulvey, Emily BergslandManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jessica Van ZiffleEmployment: Adaptive Biotechnologies (I)Stock and Other Ownership Interests: Adaptive Biotechnologies (I)Patents, Royalties, Other Intellectual Property: Adaptive Biotechnologies (I)Claire K. MulveyHonoraria: OncLive/MJH Life SciencesResearch Funding: GenentechEmily BergslandStock and Other Ownership Interests: More Health (I), Exai Bio (I)Consulting or Advisory Role: More Health (I)Research Funding: MerckPatents, Royalties, Other Intellectual Property: UpToDateNo other potential conflicts of interest were reported.